1. Home
  2. AAM vs XOMA Comparison

AAM vs XOMA Comparison

Compare AAM & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AAM
  • XOMA
  • Stock Information
  • Founded
  • AAM 2024
  • XOMA 1981
  • Country
  • AAM United States
  • XOMA United States
  • Employees
  • AAM N/A
  • XOMA N/A
  • Industry
  • AAM
  • XOMA Biotechnology: Pharmaceutical Preparations
  • Sector
  • AAM
  • XOMA Health Care
  • Exchange
  • AAM Nasdaq
  • XOMA Nasdaq
  • Market Cap
  • AAM 440.6M
  • XOMA 355.6M
  • IPO Year
  • AAM 2024
  • XOMA N/A
  • Fundamental
  • Price
  • AAM $10.05
  • XOMA $30.07
  • Analyst Decision
  • AAM
  • XOMA Strong Buy
  • Analyst Count
  • AAM 0
  • XOMA 2
  • Target Price
  • AAM N/A
  • XOMA $78.50
  • AVG Volume (30 Days)
  • AAM 95.8K
  • XOMA 32.1K
  • Earning Date
  • AAM 01-01-0001
  • XOMA 11-07-2024
  • Dividend Yield
  • AAM N/A
  • XOMA N/A
  • EPS Growth
  • AAM N/A
  • XOMA N/A
  • EPS
  • AAM N/A
  • XOMA N/A
  • Revenue
  • AAM N/A
  • XOMA $21,606,000.00
  • Revenue This Year
  • AAM N/A
  • XOMA $488.61
  • Revenue Next Year
  • AAM N/A
  • XOMA $27.42
  • P/E Ratio
  • AAM N/A
  • XOMA N/A
  • Revenue Growth
  • AAM N/A
  • XOMA 389.82
  • 52 Week Low
  • AAM $9,600.00
  • XOMA $14.33
  • 52 Week High
  • AAM $15,000.00
  • XOMA $33.78
  • Technical
  • Relative Strength Index (RSI)
  • AAM N/A
  • XOMA 51.23
  • Support Level
  • AAM N/A
  • XOMA $29.20
  • Resistance Level
  • AAM N/A
  • XOMA $31.24
  • Average True Range (ATR)
  • AAM 0.00
  • XOMA 1.42
  • MACD
  • AAM 0.00
  • XOMA -0.19
  • Stochastic Oscillator
  • AAM 0.00
  • XOMA 20.90

About AAM AA Mission Acquisition Corp. Class A Ordinary Shares

AA Mission Acquisition Corp is a blank check company.

About XOMA XOMA Corporation

XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.

Share on Social Networks: